Document is current
Any future updates will be listed below
-
Authors
Ni, Haiwei
Reitman, Zachary J. https://orcid.org/0000-0002-9122-9550
Zou, Wei
Akhtar, Md Naushad
Paul, Ritama
Huang, Menggui
Zhang, Duo https://orcid.org/0000-0003-3215-2466
Zheng, Hao
Zhang, Ruitao
Ma, Ruiying
Ngo, Gina
Zhang, Lin https://orcid.org/0000-0003-1998-0611
Diffenderfer, Eric S.
Motlagh, S. Azar Oliaei
Kim, Michele M.
Minn, Andy J.
Dorsey, Jay F.
Foster, Jessica B. https://orcid.org/0000-0002-8001-5960
Metz, James
Koumenis, Constantinos
Kirsch, David G. https://orcid.org/0000-0002-2086-205X
Gong, Yanqing https://orcid.org/0000-0001-9670-8385
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS094533, R01NS106108, R01CA241501)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA241501, P50CA190991)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL106108, R01HL106108)
Pediatric Brain Tumor Foundation
St. Baldrick's Foundation
ChadTough Foundation
- License Information
-
More Information
Article History
Received: 22 November 2023
Accepted: 7 January 2025
First Online: 5 February 2025
Competing interests
: D.G.K. is a cofounder of and stockholder in XRAD Therapeutics, which is developing radiosensitizers. D.G.K. is a member of the scientific advisory board and owns stock in Lumicell, a company commercializing intraoperative imaging technology. None of these affiliations represent a conflict of interest with respect to the work of this manuscript. D.G.K. is a coinventor on a patent for a handheld imaging device and is a coinventor on a patent for radiosensitizers. None of these patents are relevant to this manuscript. XRAD Therapeutics, Merck, Bristol Myers Squibb and Varian Medical Systems have provided research support to D.G.K. but this did not support the research described in this manuscript. Z.J.R. is listed as an inventor for intellectual property related to genetic testing for brain tumors that is managed by Duke Office of Licensing and Ventures, which is not relevant to this manuscript. The other authors declase no competing interests.
